ArticleOncology research2025
EGR1 inhibits clear cell renal cell carcinoma proliferation and metastasis via the MAPK15 pathway.
Article in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancements in Protein Kinase Inhibitors: From Discovery to Clinical Applications.Research (Washington, D.C.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clear cell renal carcinoma (ccRCC), the leading histological subtype of RCC, lacks any targeted therapy options. Although some studies have shown that early growth response factor 1 (EGR1) has a significant role in cancer development and progression, its role and underlying mechanisms in ccRCC remain poorly understood. Methods: The Cancer Genome Atlas (TCGA) database was utilized to examine the expression of EGR1 in ccRCC. The expression of EGR1 in 55 ccRCC tissues was evaluated using immunohistochemistry. The link between EGR1 expression and clinicopathological variables was examined through an analysis. Gain-of-function assays were employed to investigate EGR1's biological functions in ccRCC cells, involving proliferation, colony formation, invasion assays, and tumorigenesis in nude mice. In order to assess the protein expression of mitogen-activated protein kinase 15 (MAPK15), E-cadherin, matrix metalloproteinase-9/-2 (MMP-9 and MMP-2), Western blot technique was applied. Results: The results revealed a decrease in EGR1 expression in ccRCC tissues. This decrease was strongly linked to TNM stage, lymphatic metastasis, tumor size, histological grade, and unfavorable prognosis in ccRCC patients. It has been demonstrated that overexpressing EGR1 inhibits the growth of xenograft tumors Conclusions: The EGR1/MAPK15 axis may represent a promising target for drug development, with EGR1 serving as a possible target for ccRCC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.